{"id":"W2990602950","doi":"10.1200/jco.19.01307","title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1819,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Hazard ratio; Internal medicine; Sorafenib; Interim analysis; Adverse effect; Population; Randomized controlled trial; Intention-to-treat analysis; Hepatocellular carcinoma; Subgroup analysis; Surgery; Gastroenterology; Confidence interval; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002329075,0.00121961,0.001883647,0.0003662102,0.0004050321,0.001087159,0.0006869346,0.001258256,0.003840646],"category_scores_gemma":[0.001301859,0.0004753803,0.001243592,0.0003717969,0.0007908436,0.0008658069,0.0004130345,0.001994303,0.0008403267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006315209,"about_ca_system_score_gemma":0.001084671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000321178,"about_ca_topic_score_gemma":0.0007032272,"domain_scores_codex":[0.999351,0.00033127,0.00005208142,0.0001105704,0.00005723791,0.0000979176],"domain_scores_gemma":[0.999348,0.000116095,0.0001635014,0.00005771978,0.00003883947,0.000275953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9390175,0.01548942,0.00134782,0.0008867689,0.0007714414,0.00009313909,0.00007549261,0.0004330517,0.007794334,0.0001775535,0.001662659,0.03225075],"study_design_scores_gemma":[0.9369054,0.05951969,0.001516531,0.00002407547,0.0002334655,0.00007185098,0.00001161553,0.0002619704,0.0006664487,0.00006846998,0.0007115534,0.000009024297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834327,0.006044195,0.0007320098,0.0006860858,0.0003814118,0.00550145,0.001054156,0.0001397249,0.002028245],"genre_scores_gemma":[0.9865154,0.002871353,0.00143433,0.001116479,0.0004585371,0.004954473,0.001034038,0.00001588231,0.001599482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003840646,"threshold_uncertainty_score":0.01284826,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1234301453155467,"score_gpt":0.4015304858931631,"score_spread":0.2781003405776164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}